These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2352420)

  • 1. Effects of splenectomy on the development of tumor-specific immunity.
    Schwarz RE; Hiserodt JC
    J Surg Res; 1990 May; 48(5):448-53. PubMed ID: 2352420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE; Vujanovic NL; Hiserodt JC
    Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats.
    Felgar RE; Hiserodt JC
    Cell Immunol; 1990 Sep; 129(2):288-98. PubMed ID: 2383892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
    Parhar RS; Lala PK
    J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of splenectomy on antitumor immune system in mice.
    Higashijima J; Shimada M; Chikakiyo M; Miyatani T; Yoshikawa K; Nishioka M; Iwata T; Kurita N
    Anticancer Res; 2009 Jan; 29(1):385-93. PubMed ID: 19331177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experimental study on immunological effect of splenectomy on tumor-bearers].
    Tanemura H; Saji S; Takekoshi T; Yamamoto S; Oshita H; Sakata K
    Nihon Geka Gakkai Zasshi; 1983 Sep; 84(9):982-6. PubMed ID: 6676670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gelatin sponge model of effector recruitment: tumoricidal activity of adherent and non-adherent lymphokine-activated killer cells after culture in interleukin-2.
    Akporiaye ET; Barbieri CA; Stewart CC; Bender JG
    J Leukoc Biol; 1991 Feb; 49(2):189-96. PubMed ID: 1991999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of splenectomy on pulmonary metastasis and growth of SC42 carcinoma transplanted into mouse liver.
    Imai S; Nio Y; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Kawabata K; Masai Y; Tobe T
    J Surg Oncol; 1991 Jul; 47(3):178-87. PubMed ID: 2072702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.
    Sarneva M; Vujanovic NL; Van den Brink MR; Herberman RB; Hiserodt JC
    Cell Immunol; 1989 Feb; 118(2):448-57. PubMed ID: 2910504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.
    Vujanovic NL; Herberman RB; Maghazachi AA; Hiserodt JC
    J Exp Med; 1988 Jan; 167(1):15-29. PubMed ID: 3257251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy.
    Kawata A; Hosokawa M; Sawamura Y; Ito K; Une Y; Shibata T; Uchino J; Kobayashi H
    Mol Biother; 1990 Dec; 2(4):221-7. PubMed ID: 2288722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.